Drug Type Small molecule drug |
Synonyms DMU 2139, DMU-2139 |
Target |
Mechanism CYP1B1 inhibitors(cytochrome P450 family 1 subfamily B member 1 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC19H15NO2 |
InChIKeyMPDPEUALCUWORP-RUDMXATFSA-N |
CAS Registry1821143-80-9 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Glaucoma | Preclinical | GB | 01 Mar 2017 | |
Glaucoma | Preclinical | GB | 01 Mar 2017 | |
Ischemia | Preclinical | GB | 01 Mar 2017 | |
Ischemia | Preclinical | GB | 01 Mar 2017 | |
Neoplasms | Preclinical | GB | 01 Mar 2017 | |
Neoplasms | Preclinical | GB | 01 Mar 2017 | |
Obesity | Preclinical | GB | 01 Mar 2017 | |
Obesity | Preclinical | GB | 01 Mar 2017 |